Overall, these data demonstrate that response to anti-IgM stimulation, which mimics the BCR engagement in the tumor microenvironment, induces activation of the BCR downstream signaling, which is heterogeneous among MCL patients’ samples. This evidence concerns the gene CD40LG and neoplasm.